Cyclerion Therapeutics, Inc. Cash Flow Statement
CYCN|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$3M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Cyclerion Therapeutics, Inc. used $3M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$3.5M | -$5.3M | -$44.1M | -$44.1M | -$77.8M | -$123.0M | -$115.3M |
| Depreciation & Amortization | - | - | $65.0K | $65.0K | $2.3M | $2.7M | $1.5M |
| Operating Cash Flow | -$3.3M | -$21.2M | -$40.6M | -$40.6M | -$72.5M | -$102.2M | -$97.5M |
| Capital Expenditures | - | - | - | $0 | $1.5M | $6.9M | $3.4M |
| Free Cash Flow | - | - | - | -$40.6M | -$74.0M | -$109.1M | -$100.9M |
| FCF Margin | - | - | - | -13673.7% | -3223.6% | -2420.8% | -2239.7% |